<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.115341</article-id><article-id pub-id-type="publisher-id">ACM-42749</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210500000_22830298.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  一例着色性干皮病(XP)伴眼周角化棘皮瘤患者的XP基因突变及角化棘皮瘤组织病理学特征
  Mutation of XP Gene and Histopathological Features of Keratoacanthoma in a Patient with Xeroderma Pigmentosum and Periocular Keratoacanthoma
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邹</surname><given-names>沈珊</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>谢</surname><given-names>可人</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邹</surname><given-names>茜</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>常州市第三人民医院，江苏 常州</addr-line></aff><aff id="aff2"><addr-line>常州市中医院，江苏 常州</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>05</month><year>2021</year></pub-date><volume>11</volume><issue>05</issue><fpage>2368</fpage><lpage>2380</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：探讨着色性干皮病(XP)伴眼周角化棘皮瘤患者的XP基因突变以及角化棘皮瘤组织病理学特征。方法：手术切除该患者眼周角化棘皮瘤并行组织病理学检查。提取该患者外周血白细胞DNA，PCR扩增XP系列基因的编码外显子区域，通过直接测序比较该患者与正常人序列差异以确定致病突变。用MutationTaster在线生物信息学软件分析变异是否有害。结果：术后切除皮损组织送组织病理学检查结果示，表皮角化过度，真皮浅层慢性炎性细胞浸润，肿物与周围界限清楚。经过手术后，电话随访半年恢复良好。基因序列分析结果显示，该患者XP系列基因存在7个错义突变，5个无义突变。错义突变分别位于XPB基因第14外显子的第260位碱基，c. 260A &gt; G (p. Lys 87 Arg)；XPC基因第9外显子的第506位碱基，c. 506T &gt; C (p. Leu169Ser)；第16外显子的第211位碱基，c. 211A &gt; C (p. Ser 71 Arg)；XPF基因第11外显子的第488位碱基，c. 488C &gt; T (p. Pro 163Leu)；XPG基因第2外显子的第50位碱基，c. 50C &gt; T (p. Thr17Met)；第8外显子的第706位碱基，c. 706C &gt; G (p. Leu 236Val)；第15外显子的第346位碱基，c. 346C &gt; G (p. Thr117Met)。无义突变分别位于XPB基因第14外显子的第312位碱基；XPC基因外显子第8外显子的第39位碱基；XPD基因外显子第6外显子的第108位碱基；XPG基因第4外显子的第48位碱基；XPI基因第3外显子的第33位碱基。经MutationTaster在线生物信息学软件分析结果显示：XPC基因第9外显子，c. 506T &gt; C (p. Leu169Ser)，以及XPC基因第16外显子，c. 211A &gt; C (p. Ser 71 Arg)变异为有害突变。结论：该患者确诊为着色性干皮病伴眼周角化棘皮瘤。XPC基因突变(第9外显子，c. 506T &gt; C (p. Leu169Ser)，以及XPC基因第16外显子，c. 211A &gt; C (p. Ser 71 Arg))可能为该患者的致病突变。 
   Objective: To investigate the XP gene mutation and histopathological characteristics of periocular keratoacanthoma in patients with xeroderma pigmentosa (XP). Methods: The periocular keratoacanthoma was resected and histopathological examination was performed. DNA was extracted from peripheral blood leukocytes of the patient, the exon region of XP gene was amplified by PCR. The difference between the patient and the normal was compared by direct sequencing to determine the pathogenic mutation. Results: Histopathological examination showed hyperkeratosis of the epidermis, chronic infiltration of inflammatory cells in the superficial dermis, there is a clear boundary between the tumor and the surrounding. The results of gene sequence analysis showed that there were 7 missense mutations and 5 nonsense mutations in XP gene. The missense mutations were located at c. 260A &gt; G (p. Lys 87 Arg) in exon 14 of XPB gene; c. 506T &gt; C (p. Leu169Ser) in exon 9 and c. 211A &gt; C (p. Ser 71 Arg) in exon 16of XPC gene; c. 488C &gt; T (p. Pro 163Leu) in exon 11 of XPF gene; c. 50C &gt; T (p. Thr17Met) in exon 2, c. 706C &gt; G (p. Leu 236Val) in exon 8 and c. 706C &gt; G (p. Leu 236Val) in exon 15 of XPG gene. The nonsense mutations were located at c. 312A &gt; Gin exon 14 of XPB gene; c. 39T &gt; C in exon 8 of XPC gene, c. 108C &gt; A in exon 6 of XPD gene, c. 48A &gt; T in exon 4 of XPG gene and c. 33C &gt; T in exon 3 of XPI gene. Telephone follow-up for half a year recovered well after the operation. The results showed that c. 506T &gt; C (p. Leu169Ser) in exon 9 and c. 211A &gt; C (p. Ser 71 Arg) in exon 16 of XPC gene, were harmful mutations. Conclusion: The patient was diagnosed as xeroderma pigmentosum with periocular keratoacanthoma. XPC gene mutation (c. 506T &gt; C (p. Leu169Ser) in exon 9 and c. 211A &gt; C (p. Ser 71 Arg) in exon 16) may be pathogenic mutations in this patient.
 
</p></abstract><kwd-group><kwd>着色性干皮病，眼周角化棘皮瘤，基因突变, Xerogpimentosum</kwd><kwd> Keratoacanthoma</kwd><kwd> Gene Mutation</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨着色性干皮病(XP)伴眼周角化棘皮瘤患者的XP基因突变以及角化棘皮瘤组织病理学特征。方法：手术切除该患者眼周角化棘皮瘤并行组织病理学检查。提取该患者外周血白细胞DNA，PCR扩增XP系列基因的编码外显子区域，通过直接测序比较该患者与正常人序列差异以确定致病突变。用MutationTaster在线生物信息学软件分析变异是否有害。结果：术后切除皮损组织送组织病理学检查结果示，表皮角化过度，真皮浅层慢性炎性细胞浸润，肿物与周围界限清楚。经过手术后，电话随访半年恢复良好。基因序列分析结果显示，该患者XP系列基因存在7个错义突变，5个无义突变。错义突变分别位于XPB基因第14外显子的第260位碱基，c. 260A &gt; G (p. Lys 87 Arg)；XPC基因第9外显子的第506位碱基，c. 506T &gt; C (p. Leu169Ser)；第16外显子的第211位碱基，c. 211A &gt; C (p. Ser 71 Arg)；XPF基因第11外显子的第488位碱基，c. 488C &gt; T (p. Pro 163Leu)；XPG基因第2外显子的第50位碱基，c. 50C &gt; T (p. Thr17Met)；第8外显子的第706位碱基，c. 706C &gt; G (p. Leu 236Val)；第15外显子的第346位碱基，c. 346C &gt; G (p. Thr117Met)。无义突变分别位于XPB基因第14外显子的第312位碱基；XPC基因外显子第8外显子的第39位碱基；XPD基因外显子第6外显子的第108位碱基；XPG基因第4外显子的第48位碱基；XPI基因第3外显子的第33位碱基。经MutationTaster在线生物信息学软件分析结果显示：XPC基因第9外显子，c. 506T &gt; C (p. Leu169Ser)，以及XPC基因第16外显子，c. 211A &gt; C (p. Ser 71 Arg)变异为有害突变。结论：该患者确诊为着色性干皮病伴眼周角化棘皮瘤。XPC基因突变(第9外显子，c. 506T &gt; C (p. Leu169Ser)，以及XPC基因第16外显子，c. 211A &gt; C (p. Ser 71 Arg))可能为该患者的致病突变。</p></sec><sec id="s2"><title>关键词</title><p>着色性干皮病，眼周角化棘皮瘤，基因突变</p></sec><sec id="s3"><title>Mutation of XP Gene and Histopathological Features of Keratoacanthoma in a Patient with Xeroderma Pigmentosum and Periocular Keratoacanthoma</title><p>Shenshan Zou<sup>1</sup>, Keren Xie<sup>2</sup>, Xi Zou<sup>2*</sup></p><p><sup>1</sup>The Chinese Medicine Hospital of Changzhou, Changzhou Jiangsu</p><p><sup>2</sup>The Third People’s Hospital of Changzhou, Changzhou Jiangsu</p><p><img src="//html.hanspub.org/file/50-1572217x5_hanspub.png" /></p><p>Received: Apr. 25<sup>th</sup>, 2021; accepted: May 8<sup>th</sup>, 2021; published: May 28<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/50-1572217x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To investigate the XP gene mutation and histopathological characteristics of periocular keratoacanthoma in patients with xeroderma pigmentosa (XP). Methods: The periocular keratoacanthoma was resected and histopathological examination was performed. DNA was extracted from peripheral blood leukocytes of the patient, the exon region of XP gene was amplified by PCR. The difference between the patient and the normal was compared by direct sequencing to determine the pathogenic mutation. Results: Histopathological examination showed hyperkeratosis of the epidermis, chronic infiltration of inflammatory cells in the superficial dermis, there is a clear boundary between the tumor and the surrounding. The results of gene sequence analysis showed that there were 7 missense mutations and 5 nonsense mutations in XP gene. The missense mutations were located at c. 260A &gt; G (p. Lys 87 Arg) in exon 14 of XPB gene; c. 506T &gt; C (p. Leu169Ser) in exon 9 and c. 211A &gt; C (p. Ser 71 Arg) in exon 16of XPC gene; c. 488C &gt; T (p. Pro 163Leu) in exon 11 of XPF gene; c. 50C &gt; T (p. Thr17Met) in exon 2, c. 706C &gt; G (p. Leu 236Val) in exon 8 and c. 706C &gt; G (p. Leu 236Val) in exon 15 of XPG gene. The nonsense mutations were located at c. 312A &gt; Gin exon 14 of XPB gene; c. 39T &gt; C in exon 8 of XPC gene, c. 108C &gt; A in exon 6 of XPD gene, c. 48A &gt; T in exon 4 of XPG gene and c. 33C &gt; T in exon 3 of XPI gene. Telephone follow-up for half a year recovered well after the operation. The results showed that c. 506T &gt; C (p. Leu169Ser) in exon 9 and c. 211A &gt; C (p. Ser 71 Arg) in exon 16 of XPC gene, were harmful mutations. Conclusion: The patient was diagnosed as xeroderma pigmentosum with periocular keratoacanthoma. XPC gene mutation (c. 506T &gt; C (p. Leu169Ser) in exon 9 and c. 211A &gt; C (p. Ser 71 Arg) in exon 16) may be pathogenic mutations in this patient.</p><p>Keywords:Xerogpimentosum, Keratoacanthoma, Gene Mutation</p><disp-formula id="hanspub.42749-formula51"><graphic xlink:href="//html.hanspub.org/file/50-1572217x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/50-1572217x8_hanspub.png" /> <img src="//html.hanspub.org/file/50-1572217x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>着色性干皮病(xerogpimentosum, XP)是一种常染色体隐性遗传病，是经紫外线照射后皮肤发生光敏感，继而出现皮肤脱屑、褐色斑点及斑块，甚至可致皮肤癌、眼部损伤及内脏肿瘤的1种罕见疾病 [<xref ref-type="bibr" rid="hanspub.42749-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.42749-ref2">2</xref>]。XP是第一个被发现的与损伤DNA修复缺陷有关的疾病 [<xref ref-type="bibr" rid="hanspub.42749-ref3">3</xref>]，可累及各种族人群，以日本人和中东人发病率最高。通过细胞融合技术发现，将不同XP患者的成纤维细胞相互融合形成的杂种细胞可以重新获得损伤DNA修复的能力，提示我们XP具有多型性且各型之间互补 [<xref ref-type="bibr" rid="hanspub.42749-ref4">4</xref>]。美国国家生物技术信息中心(The National Center for Biotechnology Information, NCBI)的生物医学信息检索系统PubMed (http://www.ncbi.nlm.nih.gov/pubmed/)目前显示涉及XP的致病基因包括XPA、XPB(ERCC3)、XPC、XPD(ERCC2)、XPE(DDB1)、XPF(ERCC4)、XPG(ERCC5)、XPH(POLH)、XPI(ERCC1)。角化棘皮瘤(keratoacanthoma)是一种生长迅速的皮肤肿瘤，好发于中老年 [<xref ref-type="bibr" rid="hanspub.42749-ref5">5</xref>]。本研究对确诊的1例XP伴眼周角化棘皮瘤患者的临床、组织病理学以及基因学特点进行分析，旨在探讨着色性干皮病的基因认识以及角化瘤的病理。</p></sec><sec id="s6"><title>2. 研究对象与方法</title><sec id="s6_1"><title>2.1. 研究对象病史采集</title><p>研究对象为常州市中医院就诊的1个着色性干皮病患者(图1)。生活在江苏常州，71岁女性，否认家族史，否认近亲结婚史。临床表现为面部可见大小不等、形状不规则的褐色色素沉着斑及色素脱失斑，左眼下睑下方近鼻根部，2个月内迅速长出一条状肿物垂直于皮肤面，状如香烟，大小为18 mm &#215; 4 mm &#215; 4 mm，其根部皮肤轻度红肿，皮肤表面见灰褐色斑片，肿物边界清晰。双眼鼻侧球结膜及其下组织增生至角膜缘内约5 cm，颈部宽约4 cm。双眼晶状体浑浊。本研究严格遵循赫尔辛基宣言，所有研究均征得患者的知情同意。</p></sec><sec id="s6_2"><title>2.2. 实验方法</title><sec id="s6_2_1"><title>2.2.1. 手术切除肿物以及标本处理</title><p>行左眼下睑皮肤新生物切除 + 皮瓣修补术。切除肿物长度约2 cm，切面呈灰褐色，质硬。切除的标本经4%甲醛固定，常规脱水、包埋、切片、脱蜡，苏木精–伊红(HE)染色，于光镜下观察。术后一周复查拆线并进行电话随访。</p></sec><sec id="s6_2_2"><title>2.2.2. 外周血DNA提取</title><p>采用苯酚/氯仿/异戊醇法提取外周血中基因组DNA，并对DNA进行质量检测：① 取5 μL DNA溶液1%琼脂糖、1 &#215; TAE缓冲溶液电泳(电压120~180 V)检测，单一条带说明DNA完整无降解，有明显的条带说明浓度可以满足PCR要求；② Nanodrop测定所有血样DNA浓度和纯度，取OD<sub>260</sub>/OD<sub>280</sub>比值1.6~1.9纯度要求的DNA。将DNA浓度稀释到50 μg/ml，登记后放入−20℃冰箱保存备用。</p></sec><sec id="s6_2_3"><title>2.2.3. 引物设计</title><p>设计引物软件用Primer Premier 5，一般参数：引物长度在18~30 bp；Tm值在55~65度，退火温度在60℃左右；GC含量40%~70%；要特别注意避免引物二聚体和非特异性扩增的存在；PCR扩增产物长度：位点测序引物在150~300 bp左右，外显检测引物离外显子上下游150 bp左右；目的基因测序的PCR产物条带一般不超过1200 bp。</p></sec><sec id="s6_2_4"><title>2.2.4. XP基因序列扩增</title><p>突变筛查采用高通量测序技术对9个遗传性XP相关基因(XPA、XPB(ERCC3)、XPC、XPD(ERCC2)、XPE(DDB1)、XPF(ERCC4)、XPG(ERCC5)、XPH(POLH)、XPI(ERCC1))进行突变筛查，用NextSeq500 (美国Illumina公司)测序仪进行高通量测序。从GenBank获取基因组序列(https://www.ncbi.nlm.nih.gov/gene)。引物软件用Primer Premier 5设计引物，引物序列见表1~9。</p><p>采用PCR法扩增其编码区，引物序列和PCR退火温度。以基因组DNA为模板，通过PCR反应对目的片段进行扩增。PCR反应体系为30 μl，包括模板基因组DNA1μl (50 ng/μl)，10 &#215; Buffer缓冲液5 μl，10 mmol/L脱氧核糖核苷酸(dNTP) 5 μl，Taq DNA聚合酶0.25 μl，上、下游引物各0.5 μl (10 mmol/L)。反应条件为：95℃预变性3 min，95℃变性30 s，退火63℃~53℃ 30 s，72℃延伸45 s，共20个循环。电泳检测PCR产物(图1)。将PCR产物送上海生工生物工程股份有限公司测序。测序仪为3730DNAsequencer。进行双向测序；对正向测序发现双峰或杂峰及BLAST后DNA变异样本进行2次独立PCR产物正反向测序予以验证。</p></sec></sec><sec id="s6_3"><title>2.3. 序列比对以及突变分析</title><p>将上述基因片段的测序结果与Genebank中获取XP基因序列进行比对，使用DNAstar软件(DNASTAR Inc, Madison, WI)中SeqMan程序进行分析。用Mutation Taster (http://www.mutationtaster.org/)在线生物信息学软件分析突变位点序列的保守性以及变异是否有害。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 组织病理学检查结果</title><p>切除肿物送组织病理学检查结果示，表皮角化过度，真皮浅层慢性炎性细胞浸润，HE染色镜下见肿物表面过度角化，边缘表皮增生向中央包绕，底部呈假上皮瘤样增生，形成不规则的上皮团块及角化物，肿物与周围界限清楚，周围间质内可见大量淋巴细胞、嗜酸性粒细胞及组织细胞浸润(图2)。患者术后半年电话随访肿物未复发。</p></sec><sec id="s7_2"><title>3.2. 基因测序结果</title><p>经基因序列分析发现，在XP基因外显子内，该患者cDNA碱基出现改变(图3~7)。检测到的突变分别位于cDNA的：</p><p>XPB基因第14外显子的第260位碱基，患者该位点存在一个杂合的点突变，碱基由A变为G，导致编码的氨基酸由赖氨酸(Lys, K)变成精氨酸(Arg, R) (图3)；第14外显子的第312位碱基，患者该位点存在一个杂合的点突变，碱基由A变为G，突变前后编码的氨基酸不变，该突变为无义突变(图4)；</p><p>XPC基因第8外显子的第39位碱基，患者该位点存在一个杂合的点突变，碱基由T变为C，突变前后编码的氨基酸不变，该突变为无义突变(图5)；第9外显子的第506位碱基，患者该位点存在一个杂合的点突变，碱基由T变为C，导致编码的氨基酸由亮氨酸(Leu, L)变成丝氨酸(Ser, S) (图6)；第16外显子的第211位碱基，患者该位点存在一个杂合的点突变，碱基由A变为C，导致编码的氨基酸由丝氨酸(Ser, S)变成精氨酸(Arg, R) (图7)；</p><p>XPD基因第6外显子的第108位碱基，患者该位点存在一个杂合的点突变，碱基由C变为A，突变前后编码的氨基酸不变，该突变为无义突变(图8)；</p><p>XPF基因第11外显子的第488位碱基，患者该位点存在一个杂合的点突变，碱基由C变为T，导致编码的氨基酸由脯氨酸(Pro, P)变成亮氨酸(Leu, L) (图9)；</p><p>XPG基因第2外显子的第50位碱基，患者该位点存在一个杂合的点突变，碱基由C变为T，导致编码的氨基酸由苏氨酸(Thr, T)变成甲硫氨酸(Me) (图10)；第4外显子的第48位碱基，患者该位点存在一个杂合的点突变，碱基由C变为T，突变前后编码的氨基酸不变，该突变为无义突变(图11)；第8外显子的第108位碱基，患者该位点存在一个杂合的点突变，碱基由C变为G，导致编码的氨基酸由亮氨酸(Leu, L)变成缬氨酸(Val) (图12)；第15外显子的第346位碱基，患者该位点存在一个杂合的点突变，碱基由C变为G，导致编码的氨基酸由苏氨酸(Thr, T)变成甲硫氨酸(Met) (图13)；</p><p>XPI基因第3外显子的第33位碱基，患者该位点存在一个杂合的点突变，碱基由C变为T，突变前后编码的氨基酸不变，该突变为无义突变(图14)。</p><p>MutationTaster在线生物学信息软件对以上7个错义突变分析，得出“phylop”和“phastcons”值(phylop为正数即保守，数字越大越保守，负数即不保守。phastcons是一个0~1的值，越接近1越保守，越接近0越不保守。)</p><p>XPB基因第14外显子，c. 260A &gt; G (p. Lys 87 Arg)，“phylop”和“phastcons”值分别为“−0.609”和“0”。该位点序列不保守，变异对蛋白影响不大。</p><p>XPC基因第9外显子，c. 506T &gt; C (p. Leu169Ser)，“phylop”和“phastcons”值分别为“0.207”和“0.995”。该位点序列保守，变异为有害突变。</p><p>XPC基因第16外显子，c. 211A &gt; C (p. Ser 71 Arg)，phylop”和“phastcons”值分别为“0.897”和“1”。该位点序列保守，变异为有害突变。</p><p>XPF基因第11外显子，c. 488C &gt; T (p. Pro 163Leu)，phylop”和“phastcons”值分别为“−4.574”和“0”。该位点序列不保守，变异对蛋白影响不大。</p><p>XPG基因第2外显子，c. 50C &gt; T (p. Thr17Met)，phylop”和“phastcons”值分别为“−0.189”和“0.978”。该位点序列不保守，变异对蛋白影响不大。</p><p>XPG基因第8外显子，c. 706C &gt; G (p. Leu 236Val)，phylop”和“phastcons”值分别为“0.122”和“0.058”。该位点序列低度保守，变异为轻度有害突变。</p><p>XPG基因第15外显子，c. 346C &gt; G (p. Thr117Met)，phylop”和“phastcons”值分别为“0.178”和“0.053”。该位点序列低度保守，变异为轻度有害突变。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Primer sequence of XPA gene amplificatio</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >外显子</th><th align="center" valign="middle" >上游引物(5'-3')</th><th align="center" valign="middle" >下游引物(5'-3')</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >AGCCGAGGTGCAGCGAAGAA</td><td align="center" valign="middle" >TGTTGGGCTCTATGACTGGCACT</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >AGAAAGAAGTAAAACAGCATC</td><td align="center" valign="middle" >TCTGTGGCTTTAGTTACCCA</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >CCTTGTACATGGCTGGGATTCAGA</td><td align="center" valign="middle" >AAGGCCCCACTCCTCTGACC</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >ACCATGAGAGTTGCAGGAAAAAGT</td><td align="center" valign="middle" >TGTGAAGCATATGCAAAACTAGGGA</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >CCTGCAGATCAGAAGTCAAGTCG</td><td align="center" valign="middle" >TGGTAAAACACAATCCTTCACGA</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >TTGCATACCACCAACCCACA</td><td align="center" valign="middle" >TGACTTAGCCTTTCTCCAAGC</td></tr></tbody></table></table-wrap><p>表1. XPA基因扩增的引物序列</p><table-wrap-group id="2"><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Primer sequence of XPB(ERCC3) gene amplificatio</title></caption><table-wrap id="2_1"><table><tbody><thead><tr><th align="center" valign="middle" >外显子</th><th align="center" valign="middle" >上游引物(5'-3')</th><th align="center" valign="middle" >下游引物(5'-3')</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >TAGAGAAATGAACAGTGGAGGACC</td><td align="center" valign="middle" >CACCGCTTGGCAGCATTT</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >GGGATGCAGGTGGCTCTTAG</td><td align="center" valign="middle" >TGTTGCCTTGGGCTGTTCC</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >CTGTGGTGTTGGGCAGCTTAT</td><td align="center" valign="middle" >TGGCTACAATGGGCCTGAAT</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >AGGCACATCTGACCACTTTAGGA</td><td align="center" valign="middle" >CCTTCGCCAAATCTGTACCAT</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >TGAGGCTTGTATTTCCAGACCAT</td><td align="center" valign="middle" >AATGGGTGAAGTTGTAAAGGGTAG</td></tr></tbody></table></table-wrap><table-wrap id="2_2"><table><tbody><thead><tr><th align="center" valign="middle" >6</th><th align="center" valign="middle" >CCTGCTGGTTCTACCCTTTACA</th><th align="center" valign="middle" >AAAGCAATTCAGGGACCAACA</th></tr></thead><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >GTGTTGTTAGTCTGGGTTGCTTT</td><td align="center" valign="middle" >TTGTTCTAGCCACCATAATACCC</td></tr><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >TGTCGCTCAGATGTCAGCTATGT</td><td align="center" valign="middle" >GAGGTGGAAGTTGTGGTGAGC</td></tr><tr><td align="center" valign="middle" >9</td><td align="center" valign="middle" >GAGGCCAGGAGTTCAAGACC</td><td align="center" valign="middle" >GGTAGCAGGTGAGCCTAAGTCC</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >CAAGGGTTAGTTCAGGTGGTGTC</td><td align="center" valign="middle" >CTAATCCTCACCCACAGAAATCC</td></tr><tr><td align="center" valign="middle" >11</td><td align="center" valign="middle" >TGCCTCAGCCTCCCAAACT</td><td align="center" valign="middle" >CCTCTGACTCCAACCACCTACTT</td></tr><tr><td align="center" valign="middle" >12</td><td align="center" valign="middle" >CTACATGACGAGGGCTTTCTACT</td><td align="center" valign="middle" >AGTCTGCTCCTTCCACTAACCC</td></tr><tr><td align="center" valign="middle" >13</td><td align="center" valign="middle" >ATAGACCCTGGTATAAAGAGGAGAA</td><td align="center" valign="middle" >GAAATAATGATGGGCCATAAGGAT</td></tr><tr><td align="center" valign="middle" >14</td><td align="center" valign="middle" >AGTTCAGGTGGTAACCCCGAG</td><td align="center" valign="middle" >CTAATGCTTGGTGCCTGCCT</td></tr><tr><td align="center" valign="middle" >15</td><td align="center" valign="middle" >TAAAGGCGGCTCCTGATGC</td><td align="center" valign="middle" >CATCCTGGGCTTCAACATCAA</td></tr><tr><td align="center" valign="middle" >16</td><td align="center" valign="middle" >AACAATGCCTGAGACAGTAAGC</td><td align="center" valign="middle" >CTCCATCTTACTCATCTGTGCTTG</td></tr></tbody></table></table-wrap></table-wrap-group><p>表2. XPB(ERCC3)基因扩增的引物序列</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Primer sequence of XPC gene amplificatio</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >外显子</th><th align="center" valign="middle" >上游引物(5'-3')</th><th align="center" valign="middle" >下游引物(5'-3')</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >AAACCTGTTGTGCTCTTTCCTG</td><td align="center" valign="middle" >CTTCCTGGGACACAAATAACTGC</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >GGGTTTGGAGACAGGTCATAGAG</td><td align="center" valign="middle" >CGTGCTTGAGGACAGTAGTATGA</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >ATGTTGATGGAGGAAGTGAGGC</td><td align="center" valign="middle" >AAGCCTGTGCTCCTTCTCCTAA</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >GATTCAACCCAGTATCTCTATGCTT</td><td align="center" valign="middle" >GGTAAGATAACGGATGACCTGCT</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >GAAGTGAGCTTTGAGGCATGTAG</td><td align="center" valign="middle" >GCAAGTGCTCTTTATTTAGCCTCT</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >CCTTTGAAGGAATGAGTATACAGAG</td><td align="center" valign="middle" >ATTACCTGGTATGTATTTGTCTCCC</td></tr><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >GTGATGATAGGAGTTAGCTAGACGG</td><td align="center" valign="middle" >GTACACCACAACTAGAGGCGATA</td></tr><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >GGATGCTTTTTCAAATATACGTGTA</td><td align="center" valign="middle" >TACAGAACAGAACAAAAGCAGCACT</td></tr><tr><td align="center" valign="middle" >9</td><td align="center" valign="middle" >TAGCCAATACATACATACAACCCTG</td><td align="center" valign="middle" >TACCTCCAAGTCTTCTTTCTTCTCC</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >TATAGACCAGTGGCTAGAGGTGTTC</td><td align="center" valign="middle" >ATGGGTTATTCCTTCTTTCACTCAG</td></tr><tr><td align="center" valign="middle" >11</td><td align="center" valign="middle" >TGCCACAAGCCACAGATTTATT</td><td align="center" valign="middle" >TATTCCTTCCTTTTGTATGTTTTTG</td></tr><tr><td align="center" valign="middle" >12</td><td align="center" valign="middle" >GCAGAGGAGAAGAAAACCTATGAAG</td><td align="center" valign="middle" >AATGCTCAGTGAACTGCCAAAC</td></tr><tr><td align="center" valign="middle" >13</td><td align="center" valign="middle" >CTGAGGCAGGAGAATTGCTTAAA</td><td align="center" valign="middle" >GGTACACATTCCCAAACTCGTTC</td></tr><tr><td align="center" valign="middle" >14</td><td align="center" valign="middle" >GAGGAACTGGATGCCTTTGTTGTAA</td><td align="center" valign="middle" >AGCCTCACCCATCATGGAACAG</td></tr><tr><td align="center" valign="middle" >15</td><td align="center" valign="middle" >AGTGAGCAAAAAACAGTCAGCATC</td><td align="center" valign="middle" >CTGAAAGCCACAAAAACAGATAAC</td></tr><tr><td align="center" valign="middle" >16</td><td align="center" valign="middle" >TTCTGGAAGACCTCACCCACTAA</td><td align="center" valign="middle" >TAAAAACAAGCGGCCTTAGAGAC</td></tr><tr><td align="center" valign="middle" >17</td><td align="center" valign="middle" >TGTCCTCCCAGAGTTACACAGCTT</td><td align="center" valign="middle" >GCAAAGTGTTCTGTAGCTCAAAGG</td></tr></tbody></table></table-wrap><p>表3. XPC基因扩增的引物序列</p><table-wrap-group id="4"><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Primer sequence of XPD(ERCC2) gene amplificatio</title></caption><table-wrap id="4_1"><table><tbody><thead><tr><th align="center" valign="middle" >外显子</th><th align="center" valign="middle" >上游引物(5'-3')</th><th align="center" valign="middle" >下游引物(5'-3')</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >GCTCTGCCCTAGCGGATTG</td><td align="center" valign="middle" >CTCGCTATCACTGCTGCTCC</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >TCCTGAGGACCTGAGGGTTACC</td><td align="center" valign="middle" >CCAGCCTATTCACCATTATTGTTT</td></tr><tr><td align="center" valign="middle" >3-4</td><td align="center" valign="middle" >TTCAAACCCACTGCCCAATC</td><td align="center" valign="middle" >TCGCCCTCCTGCTTCTCATA</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >TGGAGGTGACCAAACTCATCTACT</td><td align="center" valign="middle" >GGGCCACGATGAATGAGAAT</td></tr><tr><td align="center" valign="middle" >6-7</td><td align="center" valign="middle" >CTTGTATCCCTGCATTAAGTTCC</td><td align="center" valign="middle" >CAGACTCACAGCAAGCAACAGAC</td></tr><tr><td align="center" valign="middle" >8-9</td><td align="center" valign="middle" >GGTGCCCGTATCTGTTGGTCT</td><td align="center" valign="middle" >GGCAACCCTGGGGACAAG</td></tr><tr><td align="center" valign="middle" >10-11</td><td align="center" valign="middle" >CAACGTCTGCATCGACTCCAT</td><td align="center" valign="middle" >CTCGCCCAGCTCACTCACT</td></tr><tr><td align="center" valign="middle" >12</td><td align="center" valign="middle" >CGGCAATGGCTATTTGTGAC</td><td align="center" valign="middle" >TTACTCAAGAACTATGTATGGCTCC</td></tr></tbody></table></table-wrap><table-wrap id="4_2"><table><tbody><thead><tr><th align="center" valign="middle" >13-14-15</th><th align="center" valign="middle" >GTCATGTTTGGTCGCATTTACTC</th><th align="center" valign="middle" >ATCCCGAACCCAGCCTCTT</th></tr></thead><tr><td align="center" valign="middle" >16</td><td align="center" valign="middle" >AGGCGGGATGGTCACTTGA</td><td align="center" valign="middle" >GAAACTCTGGGCTGAGCAACT</td></tr><tr><td align="center" valign="middle" >17</td><td align="center" valign="middle" >TGCTGGGATTACAGGCGTG</td><td align="center" valign="middle" >CAAGGAACCTAGAACGTGGG</td></tr><tr><td align="center" valign="middle" >18</td><td align="center" valign="middle" >CCCTTCTGCACTCATTTCATTG</td><td align="center" valign="middle" >CTGCTTACACCCCATTCCTACAT</td></tr><tr><td align="center" valign="middle" >19</td><td align="center" valign="middle" >CCACCCTCCCTCACCACATC</td><td align="center" valign="middle" >CCCAGGATGCTGTGTCTGAGTT</td></tr><tr><td align="center" valign="middle" >20-21</td><td align="center" valign="middle" >GACTTTGGTGAGTGGACTGGG</td><td align="center" valign="middle" >ACAGAAGGTCATTCGGGGAG</td></tr><tr><td align="center" valign="middle" >22</td><td align="center" valign="middle" >CCAGGCTGTTTCCCGTTCA</td><td align="center" valign="middle" >GGCACGTAGATGCACGATAAACT</td></tr><tr><td align="center" valign="middle" >23</td><td align="center" valign="middle" >TACGGACATCTCCAAATTCATTCA</td><td align="center" valign="middle" >CTGTGCCTGTCTCCAGTTTCC</td></tr></tbody></table></table-wrap></table-wrap-group><p>表4. XPD(ERCC2)基因扩增的引物序列</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Primer sequence of XPE(DDB1) gene amplificatio</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >外显子</th><th align="center" valign="middle" >上游引物(5'-3')</th><th align="center" valign="middle" >下游引物(5'-3')</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >GAGTGAGCGACAGAGCCAGAC</td><td align="center" valign="middle" >GTGCAGCTAACAAGCGTGACTA</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >GGAACCCTGCACGACTGTAT</td><td align="center" valign="middle" >TCCAAGTCCTCCCACCAAA</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >TTGGTTCACCAGCTTGTCAGA</td><td align="center" valign="middle" >CAGGCTGGAGTGTAATGGTGC</td></tr><tr><td align="center" valign="middle" >3’</td><td align="center" valign="middle" >AATGTCTTATGTTGTAAAGGTCCCA</td><td align="center" valign="middle" >TTTTAGTAGAGACGGGGTTTCAC</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >AATTAGCTGGGCATGGTGG</td><td align="center" valign="middle" >TAGTGAGGGTCAAGGTCCAGTC</td></tr><tr><td align="center" valign="middle" >4’</td><td align="center" valign="middle" >AAAGAAGTGAAGGCCCTGTAGAG</td><td align="center" valign="middle" >TGAGGGTCAAGGTCCAGTCTAAT</td></tr><tr><td align="center" valign="middle" >5-6</td><td align="center" valign="middle" >ATCCACGGCAAGACAGTTATTC</td><td align="center" valign="middle" >TAGACAGGAGCGGAAAGGAAG</td></tr><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >CCCTGCCTGTCTGACCACTG</td><td align="center" valign="middle" >GCTGAGAAGACAGAACAGAGGGT</td></tr><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >GGGGTTTCACCATGTTAGCC</td><td align="center" valign="middle" >TGAGCCAAGATCACGCCAC</td></tr><tr><td align="center" valign="middle" >9</td><td align="center" valign="middle" >CAAAGTGTTGAGATTACAGGTGTG</td><td align="center" valign="middle" >CAAGACAAAGCCAGAGGAATG</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >GGCTCAATGCAAGCTCCG</td><td align="center" valign="middle" >TCCCTCTGCTACCACCCACT</td></tr><tr><td align="center" valign="middle" >10’</td><td align="center" valign="middle" >TATTTTTAGTAGAGACAGGGTTTCG</td><td align="center" valign="middle" >CTGAGAGGAGAAAAGTCATTTAGTT</td></tr></tbody></table></table-wrap><p>表5. XPE(DDB1)基因扩增的引物序列</p><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> Primer sequence of XPF(ERCC4) gene amplificatio</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >外显子</th><th align="center" valign="middle" >上游引物(5'-3')</th><th align="center" valign="middle" >下游引物(5'-3')</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >CACGATCATCTCAGTCTCAGCTCT</td><td align="center" valign="middle" >CTCCTAGCGACCCCTTACATAC</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >AAATGTAGACTGGTTGGCTGAA</td><td align="center" valign="middle" >CAATTCACAACAAAGTAGTCAGGA</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >CTCATACATACTCCCTCTCCTCCTT</td><td align="center" valign="middle" >CCTAAAGCTGTTGTATATGTGGGTC</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >GTAGTTTGCTGACCCTTTCCTTATC</td><td align="center" valign="middle" >GCAAAAGTCAGAGTGATGCTTATAT</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >ATTAACTGAAATGTTCTAGCCACTT</td><td align="center" valign="middle" >AACAACTAAACTTCCAGAACACAAC</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >GACAGATCACAGTAGTGGGAGG</td><td align="center" valign="middle" >GCTCCTCATGTAGCATACTTTTG</td></tr><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >TCACAGAAACAACTAACACAGAATG</td><td align="center" valign="middle" >AAAACAACATCAAACGAACAGAA</td></tr><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >TTTAAGTAATCTTGCCAGAGAGGAG</td><td align="center" valign="middle" >GCAAACCAATACCCAAAGAATA</td></tr><tr><td align="center" valign="middle" >9</td><td align="center" valign="middle" >CGAGAAATAAGCAGTAGCCCAG</td><td align="center" valign="middle" >CAAACCAATACCCAAAGAATAAAG</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >GAGAAGCCTCTAAAATTTGTGTGTT</td><td align="center" valign="middle" >ATTTCTCGTGTTTTATCATACTGCT</td></tr><tr><td align="center" valign="middle" >11</td><td align="center" valign="middle" >AAATCAAGAAGTAGTATCCGACCAA</td><td align="center" valign="middle" >AAGTACATTCTGAGTCTCAACCAAC</td></tr><tr><td align="center" valign="middle" >12</td><td align="center" valign="middle" >TTAGCAGGTATGTGTGGATTTATGA</td><td align="center" valign="middle" >GGTCCACCGTACAATCATTAAGAG</td></tr></tbody></table></table-wrap><p>表6. XPF(ERCC4)基因扩增的引物序列</p><table-wrap id="table7" ><label><xref ref-type="table" rid="table7">Table 7</xref></label><caption><title> Primer sequence of XPG(ERCC5) gene amplificatio</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >外显子</th><th align="center" valign="middle" >上游引物(5'-3')</th><th align="center" valign="middle" >下游引物(5'-3')</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >GCCATTCTCTGGACCTGTCTTT</td><td align="center" valign="middle" >CGAGGGACGACTGTACTTAGAAAA</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >ACTTTAGGTAGATCCCATGAGAGCT</td><td align="center" valign="middle" >GCCGCATCCTTGAAATAAATATA</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >TTAAGTAATAGATGGAAACTCTGGGT</td><td align="center" valign="middle" >GCCACAACTCCAAATTACCAG</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >GACCTGGTAATTTGGAGTTGTG</td><td align="center" valign="middle" >AGAGGAATAAGAATCATGAATCACC</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >TCCCTATTGCATCTCTAGTGACCT</td><td align="center" valign="middle" >AGCCATCTGTCTTTACTTTTTATCA</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >TGAATGAATTAAAGAGTGAATGGCT</td><td align="center" valign="middle" >AGTAAATGTCTATAGGCTCAAACGT</td></tr><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >AAGGAAGCTGTAGTTTTTCTTGTTA</td><td align="center" valign="middle" >CAGTTTTACAGTGTGACAATACGCT</td></tr><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >ATTCTATAAACTAGCACCCCTGGAT</td><td align="center" valign="middle" >ATTAGTGCTGGCTACGTGCTC</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >TGACGATGACGAAGATGTAAAAGT</td><td align="center" valign="middle" >TCTACGTCTCTCGTTCCTTATCTGT</td></tr><tr><td align="center" valign="middle" >9</td><td align="center" valign="middle" >AAAGACAGTGCCAGTTTACCTAATT</td><td align="center" valign="middle" >TTTACAAAAAGCCTGCATTTAGTCT</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >TTTGTGTAGGTTACTGGCTGGG</td><td align="center" valign="middle" >GTTCCTGCAGAGTGAGGGGTA</td></tr><tr><td align="center" valign="middle" >11</td><td align="center" valign="middle" >GGGTCACTGTGTGTCCCTAACTC</td><td align="center" valign="middle" >TCCTATTCCTCTATATAAGCCAAAG</td></tr><tr><td align="center" valign="middle" >12</td><td align="center" valign="middle" >TGGTTCAGAGAGACTCAGGCTAG</td><td align="center" valign="middle" >ACTGGCTTTGTACCCTTGAACTAG</td></tr><tr><td align="center" valign="middle" >13</td><td align="center" valign="middle" >TCTGTGAGGTGAGGGTAACGATA</td><td align="center" valign="middle" >AACAACAACTGAGGAGAGGGAAG</td></tr><tr><td align="center" valign="middle" >14</td><td align="center" valign="middle" >TTATGCTGGAGTCATTTATTTTGT</td><td align="center" valign="middle" >ATGTCTGCTCTATGCCCCAAA</td></tr><tr><td align="center" valign="middle" >15</td><td align="center" valign="middle" >TCATTTGAGATGTGGACTAAAGACT</td><td align="center" valign="middle" >GACAAAGCCTGTGAATACAAGATAA</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >AGAGAACTGGGTTTTGGGAGATA</td><td align="center" valign="middle" >AGCTGTTCTCCTTTGTACATTCA</td></tr></tbody></table></table-wrap><p>表7. XPG(ERCC5)基因扩增的引物序列</p><table-wrap id="table8" ><label><xref ref-type="table" rid="table8">Table 8</xref></label><caption><title> Primer sequence of XPH(POLH) gene amplificatio</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >外显子</th><th align="center" valign="middle" >上游引物(5'-3')</th><th align="center" valign="middle" >下游引物(5'-3')</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >TTTTGAGATTTCTGAACTGCTTTGT</td><td align="center" valign="middle" >ATGGAGAACATGGGAATTGGTA</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >GCTTCTATTATTGACCATCTGCCT</td><td align="center" valign="middle" >CCTTCCATGTGAGTCCTTGTGA</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >TGAGCTCTCTTATAATTGGTCTTCT</td><td align="center" valign="middle" >CTCCTGAGTAGCTGGGACTGTAG</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >ATGTGGGAAGAACAGTGAGGATAA</td><td align="center" valign="middle" >CAGCGTGTGTTTCAAAATGTTC</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >ATGCTCTCATTTGTCCTGAACCT</td><td align="center" valign="middle" >ATAGTGACCCAAGATATTGAAGCA</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >AAAACCAGTGTTCTCATTGTCCA</td><td align="center" valign="middle" >CCAAACTTGAAGCATAATATCCTAG</td></tr><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >TCCTTTGATTATGGGGAGTCTTT</td><td align="center" valign="middle" >GAGCCTAAGAGGTAGAGGTTGC</td></tr><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >CTACTGTTTCCAAACCATTGTCAC</td><td align="center" valign="middle" >TTACCTCATTGAAGGACTAATCTGT</td></tr><tr><td align="center" valign="middle" >9</td><td align="center" valign="middle" >GGTTCTCAAGACATAACATCAGCAT</td><td align="center" valign="middle" >CTGTTGGTAAAGAGTTTGGTAATGC</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >CTCATTACCTTTTCAAACCAGTCA</td><td align="center" valign="middle" >TACTTTATGACACTGCCTCCCTA</td></tr></tbody></table></table-wrap><p>表8. XPH(POLH)基因扩增的引物序列</p><table-wrap id="table9" ><label><xref ref-type="table" rid="table9">Table 9</xref></label><caption><title> Primer sequence of XPI(ERCC1) gene amplificatio</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >外显子</th><th align="center" valign="middle" >上游引物(5'-3')</th><th align="center" valign="middle" >下游引物(5'-3')</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >GACGCTATGGAGCTCTCGG</td><td align="center" valign="middle" >CTCTGCCTTAGCCCTCTCTTA</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >CAACCAGTCCCCTGCAAAC</td><td align="center" valign="middle" >GAGCTACACCAATACAGCCACA</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >TAGGAGGAGAGAGAAGCTGGAAA</td><td align="center" valign="middle" >TCTCATAGAACAGTCCAGAACACTG</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >CTGAGCCCTTAGTATTCCAGTGA</td><td align="center" valign="middle" >AAAGAAGAGATATTTAGGTGGCAGA</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >GATCTTGGCTCACTGCAACG</td><td align="center" valign="middle" >GAAGGAGAAGGGAAGGGCT</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >TAGTAGAAACGAGGTTTCACCATG</td><td align="center" valign="middle" >GAGGGTAGCAGCAGATTTGTG</td></tr><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >GCCTCGAAAGTGCTGGGAT</td><td align="center" valign="middle" >GAGACTGAAAGGTGAAAGCGAG</td></tr><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >GTCACCCATTTCCTTCCATCTC</td><td align="center" valign="middle" >CACCTCAGTCTCCCCAGTAGC</td></tr><tr><td align="center" valign="middle" >9</td><td align="center" valign="middle" >ATAAATGCTTGAGGGTATAGGGG</td><td align="center" valign="middle" >GGGAAACTGAGGAACTAAAGAAAG</td></tr></tbody></table></table-wrap><p>表9. XPI(ERCC1)基因扩增的引物序列</p><p>图1. 患者面部、肿物以及眼前节照片</p><p>图2. 肿物组织及病理切片</p><p>图3. XPB基因外显子14测序结果</p><p>图4. XPB基因外显子14测序结果</p><p>图5. XPC基因外显子8测序结果</p><p>图6. XPC基因外显子9测序结果</p><p>图7. XPC基因外显子16测序结果</p><p>图8. XPD基因外显子6测序结果</p><p>图9. XPF基因外显子11测序结果</p><p>图10. XPG基因外显子2测序结果</p><p>图11. XPG基因外显子4测序结果</p><p>图12. XPG基因外显子8测序结果</p><p>图13. XPG基因外显子15测序结果</p><p>图14. XPI基因外显子3测序结果</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>XP系一种罕见的常染色体隐性遗传病，发病率低，XP是因皮肤对紫外线照射引发的DNA脱氧胸腺嘧啶二聚体切除修复缺陷 [<xref ref-type="bibr" rid="hanspub.42749-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.42749-ref2">2</xref>]。该病多于幼年时发病，75%患者发病年龄为生后6个月至3岁，临床表现主要为：发病初期在皮肤暴露部位，如颜面部、口唇部、颈部及小腿等部位出现雀斑和皮肤发干，类似日光性皮炎，继而出现持久性网状毛细血管扩张。且在红斑基础上可出现大小不等的灰色或灰褐色斑片、雀斑样皮损或点状色素脱失斑，有时可见结痂性和大疱性损害 [<xref ref-type="bibr" rid="hanspub.42749-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.42749-ref7">7</xref>]。随着年龄增长，可致眼部损害，如结膜炎、角膜新生血管化、干眼、角膜瘢痕、睑外翻、睑缘炎、结膜黑色素沉着和白内障等，头颈部皮肤多发性肿瘤、内脏肿瘤及神经损害等，并可于3~4年内出现恶性肿瘤 [<xref ref-type="bibr" rid="hanspub.42749-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.42749-ref8">8</xref>]。XP无明显种族差异，近亲结婚为该病的危险因素之一 [<xref ref-type="bibr" rid="hanspub.42749-ref9">9</xref>]。XPA，XPE负责识别DNA中的光产物，功能上XPA验证蛋白质是否处于正确位置，然后核酸酶XPG和XPF切割两侧损伤的DNA并用完整的DNA替换。通常情况下核苷酸切除修复包括转录偶联修复以及整组修复。XPC和XPE蛋白只在整组修复中起到作用，其他的XP蛋白在两个修复过程中都有作用。因此XPC、XPE基因缺陷的患者症状相对轻一点，一般不会出现神经异常 [<xref ref-type="bibr" rid="hanspub.42749-ref10">10</xref>]。按分型标准 [<xref ref-type="bibr" rid="hanspub.42749-ref11">11</xref>]，XP分为3型：典型XP、类着色性干皮病型和XP变异型。典型XP的发病早(均在5岁前)，皮损遍及全身，DNA修复功能缺陷；XP变异型，患者有典型XP症状，同时伴发育迟缓、智力低下等神经精神症状；类着色性干皮病，虽有典型XP症状，但发病晚，皮损局限于暴露部分，症状较轻。本患者面部密集雀斑，同时伴有慢性睑缘炎、翼状胬肉、白内障等眼部损害，可诊断为XP。但发病年龄较晚，且无明显神经精神症状，属类着色性干皮病型。可能与患者采取了较好的防护措施、以及致病基因突变为XPC未能引起严重蛋白表达改变有关。</p><p>角化棘皮瘤是一种生长迅速的皮肤肿瘤 [<xref ref-type="bibr" rid="hanspub.42749-ref5">5</xref>]，其介于良性与恶性肿瘤之间，亦有学者倾向于其为恶性肿瘤，认为是一种高分化的鳞状细胞癌 [<xref ref-type="bibr" rid="hanspub.42749-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.42749-ref13">13</xref>]。角化棘皮瘤好发于中老年人皮肤暴露在日光照射部位，如面部、头颈部、前臂和手背部等 [<xref ref-type="bibr" rid="hanspub.42749-ref5">5</xref>]。角化棘皮瘤的组织病理学特征为表皮凹陷如火山口样，其中充以角栓，底部表皮凸增生呈条索状向真皮内不规则延伸，增生表皮内可见角化珠。火山口周围表皮呈唇样突出，有细胞质嗜酸性淡染的体积大的鳞状细胞伸向真皮，可见核分裂象，真皮内炎性细胞浸润明显。本例患者长于左眼下睑下方近鼻根部，切除肿物送组织病理学检查结果均证实为角化棘皮瘤。XP与角化棘皮瘤的发生均与日光暴晒有关，但XP是否可诱发角化棘皮瘤尚待进一步研究证实。</p></sec><sec id="s9"><title>基金项目</title><p>常州市科技项目(CJ20190062)。</p></sec><sec id="s10"><title>文章引用</title><p>邹沈珊,谢可人,邹 茜. 一例着色性干皮病(XP)伴眼周角化棘皮瘤患者的XP基因突变及角化棘皮瘤组织病理学特征Mutation of XP Gene and Histopathological Features of Keratoacanthoma in a Patient with Xeroderma Pigmentosum and Periocular Keratoacanthoma[J]. 临床医学进展, 2021, 11(05): 2368-2380. https://doi.org/10.12677/ACM.2021.115341</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.42749-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">陈娟, 邓丹琪, 周晓鸿, 等. 伴有家族史的着色性干皮病１例[J]. 临床皮肤科杂志, 2012, 41(1): 45-46.</mixed-citation></ref><ref id="hanspub.42749-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Black, J.O. (2016) Xeroderma Pigmentosum. Head and Neck Pathology, 10, 139-144.  
&lt;br&gt;https://doi.org/10.1007/s12105-016-0707-8</mixed-citation></ref><ref id="hanspub.42749-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Alkatan, H.M. and Maktabi, A. (2017) Corneoscleral Locally Aggressive Fibrous Histiocytoma in Xeroderma Pigmentosum Patient: A Case Report. Saudi Journal of Ophthalmology, 2019, 297-299.  
&lt;br&gt;https://doi.org/10.1016/j.sjopt.2017.08.001</mixed-citation></ref><ref id="hanspub.42749-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">侯艳霞, 张学军, 杨森. 着色性干皮病发病机制的研究进展[J]. 国际皮肤性病学杂志, 2005, 31(4): 241-243.</mixed-citation></ref><ref id="hanspub.42749-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">杨雅杰, 郑焱. 角化棘皮瘤14例临床病理特点并文献复习[J]. 中国皮肤性病学杂志, 2020, 34(2): 170-172.</mixed-citation></ref><ref id="hanspub.42749-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">赵红姝, 史季桐. 着色性干皮病继发眼部恶性肿瘤的临床特点及其手术治疗[J]. 中华眼视光学与视觉科学杂志, 2012, 4(5): 272-275.</mixed-citation></ref><ref id="hanspub.42749-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">王雪丽, 贾俊, 赵怡芳. 着色性干皮病合并唇、舌癌１例报告及文献复习[J]. 中国口腔颌面外科杂志, 2010, 8(6): 574-576.</mixed-citation></ref><ref id="hanspub.42749-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">刘积东, 张斌, 朱英华, 等. 手术治疗着色性干皮病伴发的皮肤鳞状细胞癌和基底细胞癌一例[J]. 中华皮肤科杂志, 2011, 44(11): 822.</mixed-citation></ref><ref id="hanspub.42749-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">肖明, 郭澍, 金石峰. 着色性干皮病临床治疗的研究进展[J]. 医学综述, 2010, 16(24): 3760-3763.</mixed-citation></ref><ref id="hanspub.42749-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">姬腾达, 邱海霞, 曾晶, 等. 着色性干皮病诊疗进展[J]. 中国激光医学杂志, 2019, 28(2): 112-118.</mixed-citation></ref><ref id="hanspub.42749-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">王定邦, 王秀琴, 吴旻, 等. 11例着色性干皮病临床和遗传学探讨[J]. 中华医学杂志, 1983, 63(1): 9-13.</mixed-citation></ref><ref id="hanspub.42749-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">崔红艳, 李秋静, 邹刚勇. 38例角化棘皮瘤临床病理分析[J]. 中国麻风皮肤病杂志, 2011, 27(4): 296.</mixed-citation></ref><ref id="hanspub.42749-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">刘冰梅, 尤海燕, 杨晶, 等. 角化棘皮瘤的克隆性分析[J]. 中华皮肤科杂志, 2010, 43(4): 275-276.</mixed-citation></ref></ref-list></back></article>